You just read:

AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 mcg Program At The American Society Of Anesthesiology Meeting

News provided by

AcelRx Pharmaceuticals, Inc.

Oct 23, 2015, 07:00 ET